Extended Data Fig. 9: LIMIT-GBP-HSF1 axis drives MHC-I and tumor immunity and immunotherapy.
From: LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
a-b, HSF1 signaling genes correlated with MHC-I expression (a) or CD8+ T cell infiltration (b) in Pan-Cancer (TCGA, PANCAN), melanoma (TCGA, SKCM) or sarcoma (TCGA, SARC). P value by 2-sided t-test. The minima, 25% percentile, median, 75% percentile, maxima for each blot are (a) (31.53, 40.0075, 42.87, 45.4925, 53.58), (32.02, 41.1175, 43.66, 46.205, 55), (31.82, 39.785, 43.16, 46.31, 50.39), (33.35, 42.215, 44.53, 47.55, 53.41), (32.9, 38.88, 41.19, 43.21, 47.55), (39.33, 44.75, 46.57, 48.4, 51.3); (b) (3.75, 15.6825, 23.6, 30.48, 49.23), (5.47, 19.5875, 24, 29.1525, 45.42), (7.711, 15.7925, 23.415, 29.7395, 39.722), (4.9254, 18.95, 27.857, 34.862, 47.79), (7.7582, 14.727, 18.553, 22.16, 36.084), (15.024, 22.149, 29.1, 35.582, 43.432). c, Survival plots of human melanoma patients (TCGA, SKCM). Based on the expression of HSF1 signaling genes, patients were divided into high (n = 150 patients) and low (n = 150 patients) groups. P value by 2-sided log-rank test. d, Single cell RNA-seq derived cell clusters pre- or post- anti-PD-1 therapy in human skin basal cell carcinoma. Two malignant clusters are denoted by color and show different sensitivities to PD-1 blockade. e, Expression of HSF1 signaling genes and MHC-I related genes in the single cell clusters prior to PD-1 blockade therapy. The therapy sensitive tumor cell cluster exhibited higher levels of HSF1 signaling genes and MHC-I related genes as compared to the therapy insensitive tumor cell cluster. f, Proteomics analysis in melanoma patients having received ICB. Protein expression of GBPs, HSF1 signaling genes, and HLA-ABC were compared in responders (R, n = 40 patients) and non-responders (NR, n = 27 patients). P value by 2-sided t-test. g, Based on the transcript levels of GBP1, human Pan-Cancers were divided into high (top 10%) and low (bottom 10%) groups. HSF1 target gene transcripts were plotted. mean ± SD, n = 1106 patients, P value by 2-sided t-test. The minima, 25% percentile, median, 75% percentile, maxima for each blot are (9.12, 12.29, 13.01, 13.8075, 18.2), (9.24, 12.73, 13.47, 14.19, 19.16), (5.32, 9.64, 10.625, 11.39, 15.74), (6.98, 10.365, 11.11, 11.78, 16.96), (10.86, 12.83, 13.59, 14.16, 16.68), (11.75, 13.77, 14.16, 14.5, 16.71), (10.57, 13.11, 13.84, 14.48, 16.33), (12.15, 13.96, 14.3, 14.71, 17.76). Source data are provided.
